Ofer Agid1, Gary Remington1, Carmen Fung2, Natalie M Nightingale3, Marc Duclos4, Gregory J Anger5. 1. Clinician Scientist and Psychiatrist, Centre for Addiction and Mental Health. 2. Manager of Data & Analytics Centre, 41697Janssen Inc. 3. Consultant, 380397IQVIA. 4. Director of Statistics, 380397IQVIA. 5. Medical Director, 41697Janssen Inc.
Abstract
Objective: The objective of this study was to analyze the real-world prevalence of long-acting injectable (LAI) antipsychotic use and determine when LAIs are being used in sequencing of antipsychotic medications among Canadian patients with schizophrenia. Methods: This was a retrospective, longitudinal cohort study using Canadian pharmacy prescription data between August 2005 and June 2017. Patients with inferred schizophrenia spectrum disorder were indexed on the date of their first antipsychotic prescription and analyzed for minimum 12 months to track lines of antipsychotic therapy and LAI utilization. Results: A total of 16,300 patients were identified for analysis. 48.2% and 46.0% of index antipsychotic prescriptions were prescribed by a general practitioner/family medicine doctor and psychiatrist, respectively. 1,062 (6.5%) patients used an LAI during the study period. Of those patients, 789 used an LAI within two years of index (74.3% of LAI users; 4.8% of all patients). The majority of LAI use (62.0%) occurred in the third line of therapy or later. 65.0% of patients had tried at least two therapy lines, and most patients reported gaps of six months to one year between treatment lines. Conclusion: Despite their potential to reduce relapse in schizophrenia by improving treatment adherence, this study shows LAIs continue to be under-utilized in Canada. When used, LAIs are positioned late in sequencing of antipsychotic medications, often not initiated until years after diagnosis. Continued preference for oral APs with poor adherence may be negatively impacting prognosis and exacerbating burden of schizophrenia. Efforts should be invested to understand barriers to LAI uptake and advocate for earlier, widespread use of LAIs.
Objective: The objective of this study was to analyze the real-world prevalence of long-acting injectable (LAI) antipsychotic use and determine when LAIs are being used in sequencing of antipsychotic medications among Canadian patients with schizophrenia. Methods: This was a retrospective, longitudinal cohort study using Canadian pharmacy prescription data between August 2005 and June 2017. Patients with inferred schizophrenia spectrum disorder were indexed on the date of their first antipsychotic prescription and analyzed for minimum 12 months to track lines of antipsychotic therapy and LAI utilization. Results: A total of 16,300 patients were identified for analysis. 48.2% and 46.0% of index antipsychotic prescriptions were prescribed by a general practitioner/family medicine doctor and psychiatrist, respectively. 1,062 (6.5%) patients used an LAI during the study period. Of those patients, 789 used an LAI within two years of index (74.3% of LAI users; 4.8% of all patients). The majority of LAI use (62.0%) occurred in the third line of therapy or later. 65.0% of patients had tried at least two therapy lines, and most patients reported gaps of six months to one year between treatment lines. Conclusion: Despite their potential to reduce relapse in schizophrenia by improving treatment adherence, this study shows LAIs continue to be under-utilized in Canada. When used, LAIs are positioned late in sequencing of antipsychotic medications, often not initiated until years after diagnosis. Continued preference for oral APs with poor adherence may be negatively impacting prognosis and exacerbating burden of schizophrenia. Efforts should be invested to understand barriers to LAI uptake and advocate for earlier, widespread use of LAIs.
Authors: Gary Remington; Donald Addington; William Honer; Zahinoor Ismail; Thomas Raedler; Michael Teehan Journal: Can J Psychiatry Date: 2017-07-13 Impact factor: 4.356
Authors: Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao Journal: N Engl J Med Date: 2005-09-19 Impact factor: 91.245
Authors: Benedicto Crespo-Facorro; Roberto Roiz-Santiáñez; José María Pelayo-Terán; Cesar González-Blanch; Rocío Pérez-Iglesias; Agustín Gutiérrez; Enrique Marco de Lucas; Diana Tordesillas; José Luis Vázquez-Barquero Journal: Schizophr Res Date: 2007-02-15 Impact factor: 4.939
Authors: M Alvarez-Jimenez; A Priede; S E Hetrick; S Bendall; E Killackey; A G Parker; P D McGorry; J F Gleeson Journal: Schizophr Res Date: 2012-06-01 Impact factor: 4.939
Authors: Taishiro Kishimoto; Katsuhiko Hagi; Masahiro Nitta; Stefan Leucht; Mark Olfson; John M Kane; Christoph U Correll Journal: Schizophr Bull Date: 2018-04-06 Impact factor: 9.306